Related Experiment Videos
Clinical practice. Hypersensitivity to hymenoptera stings
1Department of Allergy and Immunology, Wilford Hall Medical Center, Lackland Air Force Base, San Antonio, TX 78023, USA. tfree95900@aol.com
The New England Journal of Medicine
|November 5, 2004
Summary
No abstract available in PubMed .
Related Concept Videos
Articles linked to this work by shared authors, journal, and citation graph.
β-Blockers and angiotensin-converting enzyme inhibitors with sublingual immunotherapy: are risks related to individual product safety profile?
Current opinion in allergy and clinical immunology·2020
Sublingual Immunotherapy for Other Indications: Venom Large Local, Latex, Atopic Dermatitis, and Food.
Immunology and allergy clinics of North America·2019
Are ACE Inhibitors and Beta-blockers Dangerous in Patients at Risk for Anaphylaxis?
The journal of allergy and clinical immunology. In practice·2017
ABAI's MOC Assessment of Knowledge Program Matures: Adding Value with Continuous Learning and Assessment.
The journal of allergy and clinical immunology. In practice·2017
Cross-reactivity between allergens in the venom of the common striped scorpion and the imported fire ant.
The Journal of allergy and clinical immunology·2004
Negative venom skin test results in patients with histories of systemic reaction to a sting.
The Journal of allergy and clinical immunology·2003
Fibromyalgia.
The New England journal of medicine·2026
Health Care-Associated Infections in U.S. Hospitals, 2023 versus 2015.
The New England journal of medicine·2026
Extended Dual Antiplatelet Therapy for Multivessel Coronary Artery Disease.
The New England journal of medicine·2026
Continuous or Fixed-Duration Maintenance Therapy in Multiple Myeloma.
The New England journal of medicine·2026
Andes Virus - A Clinical Review.
The New England journal of medicine·2026
Platelet-Activating Anti-Platelet Factor 4 Disorders.
The New England journal of medicine·2026
Upadacitinib for refractory generalized lichen sclerosus: a case report and brief literature review.
Frontiers in immunology·2026
Case Report: A case report of bullous pemphigoid triggered by sintilimab (PD-1 inhibitor).
Frontiers in immunology·2026